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I N T R O D U C T I O N
Combined oral contraceptives (COCs) are the most popular form of reversible contraception in the world 1 . As COCs have evolved, the two most important formulation changes consisted of a reduction in the dose of the oestrogenic component ethinylestradiol (EE) from Ն 50 µ g to Ͻ 35 µ g per pill, and the introduction of newer progestogens. Together, these changes have helped to reduce cardiovascular events, and have improved the safety and tolerability profi les of COCs 2,3 .
The incorporation of oestrogens and progestogens that are structurally similar or identical to endogenous hormones represent the most recent change in the evolution of COCs 4,5 . In particular, 17 β -oestradiol (E2) has been investigated as an alternative to synthetic EE. Early attempts to incorporate E2 into COCs were unsuccessful due to poor cycle control, especially when administered as part of a monophasic or biphasic regimen 6 -9 . Despite these early setbacks, it is still hypothesised that the use of E2 in combination with a suitable progestogen would improve the safety of COCs and patient tolerability 10 .
Nomegestrol acetate (NOMAC) is a progestogen structurally similar to progesterone that is devoid of oestrogenic, androgenic, glucocorticoid, and mineralocorticoid activity but it exerts antioestrogenic effects on the endometrium and has a moderate antiandrogenic activity 11 . The combination of NOMAC with E2 (NOMAC/E2) was developed as a monophasic COC. Previous studies have shown that NOMAC/E2 administered in a 24/4-day dosing regimen had suppressive effects on the ovaries, cervical mucus and endometrium that were at least as strong as those of a comparator COC containing drospirenone and EE 12 .
Several studies have shown that COCs can affect adrenal and thyroid function as well as androgen levels 13 -15 . The objective of this six-cycle study was to determine the effects of NOMAC/E2 on surrogate markers of adrenal and thyroid function, androgens, androgen precursors, and sex hormone-binding globulin (SHBG) in comparison to the COC levonorgestrel (LNG)/EE (150 µ g/30 µ g). The effects of NOMAC/E2 on haemostasis, lipids, and carbohydrate metabolism were also assessed in this trial and are reported elsewhere 16 .
M E T H O D S
This study was a randomised, open-label, comparative, parallel-design clinical study. Five centres in Finland participated in the trial. Advertisements were used to recruit women from the regions surrounding the study centres (Kuopio, Tampere, Turku, Espoo, and Oulu). Throughout the trial, study volunteers were compensated for their time, travel costs, and inconvenience associated with study visits.
The study was conducted in compliance with the ethical principles described in the Declaration of Helsinki and the International Conference on Harmonisation (ICH) guideline for Good Clinical Practice (GCP). At each study centre, the Independent Ethics Committee reviewed and approved the trial protocol (NCT00511355). Prior to treatment, written informed consent was obtained from all study participants.
Participants
Healthy, sexually active women aged 18 -50 years with a body mass index (BMI) between 17 and 29 kg/m 2 were eligible for the study if they had no contraindications for the use of contraceptive steroids and had not taken any other hormonal treatment (except contraceptives) within two months prior to screening. The contraindications for contraceptives were in line with the World Health Organisation ' s medical eligibility criteria for contraceptive use 17 . Additionally, women were excluded from the study if they had an abnormal cervical smear or a clinically relevant abnormal laboratory fi nding, were breastfeeding, or if they used liver-enzymeinducing drugs, investigational drugs, or pharmacological agents that can affect haemostasis (e.g., vitamin K, nonsteroidal anti-infl ammatory drugs, including aspirin).
Treatment and study design
The objectives of this trial were to assess and compare the effects of NOMAC/E2 and LNG/EE on surrogate markers of adrenal and thyroid function, androgens, androgen precursors, and SHBG levels.
The trial consisted of one pretreatment cycle (cycle 0), followed by six 28-day treatment cycles (cycles 1 -6) 
Surrogate markers of adrenal and thyroid function
Electrochemiluminescence immunoassays (ECLIAs; Roche Diagnostics) were used to measure serum levels of total cortisol, thyroid-stimulating hormone (TSH), and free thyroxine (T 4 ). Radioimmunoassays (RIAs) were used to measure corticosteroid-binding globulin (CBG; Biosource) and thyroxine-binding globulin (TBG; Brahms).
Androgens and androgen precursors
Total testosterone was measured by ECLIA (Roche Diagnostics). Dehydroepiandrosterone sulphate (DHEAS), androstenedione, and dihydrotestosterone (DHT) were measured by radioimmunoassay (Immunotech; DPC Coat A Count, and DPC, respectively). Levels of free testosterone were calculated from total testosterone and SHBG as described by Vermeulen et al . 18 .
SHBG
Serum SHBG was measured by ECLIA (Roche Diagnostics).
Statistical analysis
The trial was set up to confi rm the expected differences in changes from baseline between the treatment groups in several metabolic indices, especially prothrombin fragment 1 ϩ 2, D-dimer, and antithrombin III, as reported elsewhere 16 . In short, based on expected effect sizes (i.e., differences between the treatment groups divided by the standard deviation) of 0.6 or higher observed in previous trials, a sample size of 42 evaluable participants per treatment group was needed using a two-sided statistical test with 80% power and a signifi cance level of 5%. This power to detect moderately large effect sizes of 0.6 was also considered appropriate for surrogate markers of adrenal and thyroid function, androgens, and androgen precursors assessed in the trial. Compensating for up to 20% premature discontinuations from treatment and accounting for a potential power loss due to the nonparametric analysis, in total 60 women were to be randomised per treatment group. and a post-treatment visit. All study visits in which blood samples needed to be taken took place in the morning, when participants were fasting. At the screening visit, eligibility for participation was determined and baseline data were collected. Women were instructed to discontinue the use of hormonal contraceptives and to use condoms whenever necessary. The fi rst menstruation after the screening visit was considered a withdrawal bleeding, and the pretreatment cycle started during the next ( ' spontaneous ' ) menstrual period. The pretreatment cycle visit occurred during the second half of this cycle. During this visit, blood was taken for baseline assessment of markers of adrenal and thyroid function, androgens, androgen precursors, and SHBG. This would ensure a period of at least six weeks between last contraceptive use and baseline measurements (i.e., four weeks until spontaneous menstruation, plus two weeks until baseline assessment). Women who were eligible for enrolement were randomised in a 1:1 ratio to receive daily either a COC containing 2.5 mg NOMAC and 1.5 mg E2, or the comparator COC containing 150 µ g LNG and 30 µ g EE. Randomisation was performed using blocks with randomly permuted block sizes and an interactive voice response system. Due to the broadened age range compared with previous trials with COCs, women were stratifi ed into two age groups (18 -35 years old and 36 -50 years old) to ensure that approximately 20% of the participants were between 36 -50 years of age at screening. For six consecutive 28-day cycles, women took one oral tablet of study medication at approximately the same time each day (day 1 to day 28). The NOMAC/E2 regimen consisted of 24 days of active pills followed by four days of placebo pills; the LNG/EE regimen consisted of 21 days of active pills followed by seven days of placebo pills. Between days 15 and 21 of treatment cycles 3 and 6, participants returned to the clinic in a fasted state and blood was collected. A fi nal visit was scheduled between 8 and 14 days after the last tablet was taken in cycle 6 or after early discontinuation of treatment for the gathering of general follow-up data.
Laboratory measurements
All laboratory examinations were performed by the Bio Analytical Research Corporation (BARC) in Gent, Belgium. A manual with complete instructions on
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The analyses of the cycle 6 assessments were considered the primary outcome, whereas the analyses of the cycle 3 assessments were regarded as secondary outcomes. Analyses were performed for all participants who had taken at least one tablet of either study medication. Summary statistics are presented as mean values with standard deviations (SDs) and median values with interquartile ranges (IQRs). Data are presented for baseline (defi ned as the last measurement before administration of the fi rst study medication) and treatment cycles 3 and 6; changes from baseline to cycle 6 were calculated per index assessed. All tests of statistical signifi cance were performed at the 5% error level. The Cochran-Mantel-Haenszel test, 95% confi dence intervals (CIs; based on the Hodges-Lehmann approach 19 ), frequency tables, and descriptive statistics were used for data analyses. No correction for multiplicity was applied.
R E S U L T S
A total of 121 women were randomised to receive either NOMAC/E2 or LNG/EE (Figure 1 ). All women in the NOMAC/E2 group ( n ϭ 60) received treatment, whereas three of the women in the LNG/EE group ( n ϭ 61) did not because of a pretreatment adverse event (AE) ( ' acne ' ), withdrawn consent, or other personal reason (found a new job). Seven women (11.7%) in the NOMAC/E2 group and six women (10.3%) in the LNG/EE group discontinued treatment before the end of the trial. Of these 13 discontinuers, eight women (four in each group) discontinued treatment due to an AE, one due to pregnancy wish, one moved to another city, and three women were lost to follow-up. Overall tablet intake compliance was high in both treatment groups: 93.1% and 87.7% of women in the NOMAC/ E2 and LNG/EE groups, respectively, took the daily tablet on at least 95% of treatment days.
The demographic and clinical characteristics were similar between the two treatment groups at baseline (Table 1) , with the exception of smoking prevalence, which was higher among women in the NOMAC/ E2 group. The majority of smokers were light smokers (15.0% and 8.6% of all NOMAC/E2 and LNG/ EE users, respectively), consuming on average less than 10 cigarettes per day. Baseline values for all measured indices were balanced between the two treatment groups (Tables 2 -4). The mean age was 28.7 years. All but one of the participants (99.2%) were White. The effects on surrogate markers of adrenal and thyroid function, androgens, androgen precursors, and SHBG were similar for the two age groups (18 -35 years old and 36 -50 years old). The greater in the LNG/EE group than in the NOMAC/ E2 group (Table 3 ). The differences between the treatment groups in change from baseline to cycle 6 were statistically signifi cant for all androgens and androgen precursors (Table 5 ; p Ͻ 0.05) except for free testosterone. Both treatments were associated with increases in median SHBG concentrations (Table 4) , with a signifi cantly greater increase in the NOMAC/E2 group (44%) compared with the LNG/ EE group (22%) at cycle 6 ( p ϭ 0.019; Table 5 ).
For all androgens, androgen precursors, and SHBG, changes from baseline to cycle 3 were in general similar to changes from baseline to cycle 6.
Contraceptive effi cacy and tolerability
No pregnancies occurred during the trial in either treatment group. NOMAC/E2 had a similar AE profi le as LNG/EE, and both COCs were generally results are therefore presented only for the age groups combined.
Analyses related to surrogate markers of adrenal and thyroid function
Total cortisol, CBG, and TBG concentrations increased from baseline to cycle 6 in both treatment groups, with a signifi cantly more pronounced rise in the LNG/EE group (Tables 2 and 5 ; p Ͻ 0.001). For TSH and free T 4 , changes from baseline to cycle 6 were small, with no statistically signifi cant differences between NOMAC/E2 and LNG/EE. For all adrenal and thyroid indices, changes from baseline to cycle 3 were similar to changes from baseline to cycle 6.
Androgens, androgen precursors, and SHBG
For androgens and androgen precursors, a decrease from baseline to cycle 6 was observed, which was 
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well tolerated. The most frequently reported AEs (for NOMAC/E2 and LNG/EE, respectively) were upper respiratory tract infection (six and fi ve participants), headache (three and seven participants), and acne (two and four participants). One serious adverse event (SAE), the worsening of a congenital mitral valve leak, was reported in the NOMAC/E2 group. Immediately after clinical evaluation, the woman was withdrawn from the study. No serious AEs were reported in the LNG/EE group. Eight women (four women in each group) discontinued treatment during the study because of an AE. Reasons for discontinuation due to an AE included depression, nausea, and a combination of tachycardia, pain in the calf, and weakness in the limb (NOMAC/E2). In the LNG/EE group, AEs that led surrogate markers that are indicative of adrenal and thyroid function, androgens, and androgen precursors. It appears that NOMAC/E2 has less infl uence than LNG/EE on these indices. While both treatments caused CBG and total cortisol levels to rise, increases were signifi cantly greater in women who received LNG/EE. Elevated CBG, which is commonly observed with COC use, is to discontinuation included decreased sexual desire, nausea, and headache.
D I S C U S S I O N
This randomised study compared the effects of NOMAC/E2 administered in a 24-day regimen with LNG/EE administered in a 21-day regimen on related to an oestrogen-induced increase in the hepatic synthesis of serum proteins 13, 20, 21 . The effect of oestrogens on protein synthesis in the liver is not counteracted by progestogens 20 . Consequently, the signifi cantly lesser increase in CBG observed in women taking NOMAC/E2 is likely the result of the substitution of EE with E2. This is in line with the fi ndings of a previously performed study, which showed that the effect of 2 mg oestradiol valerate (which is equivalent to 1.52 mg E2 22 ) on CBG was considerably less than that of 10 μ g EE 15 . The elevations in total cortisol are probably caused by an increased concentration of CBG, resulting in de-creased clearance and not by a direct effect on adrenal function. This was also concluded in previous studies that assessed the effects of COC use on total cortisol 14, 23, 24 . The increase in TBG as seen in the NOMAC/E2 group and to a greater extent in the LNG/EE group .019 * Point estimates of the difference and two-sided 95% confi dence intervals (CIs) by the Hodges-Lehmann approach. * * Differences between groups; Cochran-Mantel-Haenszel test adjusted for age class using standardised midranks, applied on changes from baseline. NOMAC/E2, nomegestrol acetate/17 β -oestradiol; LNG/EE, levonorgestrel/ethinylestradiol; CBG, corticosteroidbinding globulin; TSH, thyroid-stimulating hormone; T 4 , thyroxine; TBG, thyroxine-binding globulin; DHEAS, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; SHBG, sex hormone-binding globulin.
and sexual function cannot be determined in a relatively small trial like this. The signifi cance of these fi ndings can only be determined in large clinical studies with a suffi ciently long duration of treatment.
Since we observed an imbalance in smokers between the treatment groups (23.3% vs. 12.1% in the NOMAC/ E2 and LNG/EE groups, respectively), we investigated this factor in more detail. Although smoking was shown to have a signifi cant effect on total cortisol, androstenedione, DHT, and SHBG, with larger increases (or less pronounced decreases) in smokers in comparison to non-smokers (results not shown), analysis of variance methods based on ranks showed that all treatment effects adjusted for smoking were completely consistent with the results unadjusted for smoking.
In summary, this study demonstrated that the monophasic COC NOMAC/E2 has less infl uence on surrogate markers of adrenal and thyroid function, androgens, and androgen precursors than LNG/ EE. Large clinical or retrospective studies will be needed to determine whether these differences in surrogate endpoints have any clinical relevance.
